We are present in 38 countries with our own subsidiaries
HIPRA, a reference in research
We are a pharmaceutical multinational company dedicated to the research, production and marketing of vaccines and diagnostic products. We have over 60 years of market experience and 38 global subsidiaries.
HIPRA is a veterinary multinational dedicated to the research, production and marketing of Animal Health Prevention products. With half a century of history, we are an Animal Health company with a particular focus on Biologics (vaccines). We are currently ranked amongst the top companies in the global veterinary industry in terms of Biologics.
We are the company that has developed and launched more vaccines on to the market in the last 10 years. That’s why we invest 11% of our annual turnover in research. 16% of our workforce belongs to R&D. We offer a line of innovative biologics, diagnostic services and our own range of diagnostic kits.
HIPRA does not outsource any of its processes. This is a key aspect of our corporate identity. The performance of all processes from development to marketing provides us with knowledge, agility and rapid responsiveness.
Our portfolio includes several vaccines and diagnostic kits for different types of Coronavirus in animals, and we have experience in the production of protein expression platforms that are commonly used in human vaccines. Most of our vaccines are composed of multiple valences and give immediate protection to animals with a very short life cycle (weeks or months).
We are currently sixth in the global rankings of biological turnover
Within the range of services associated with veterinary vaccination, it is worth noting that we manufacture smart vaccination equipment and develop software to ensure vaccination quality and traceability.
Our facilities have state-of-the-art production equipment and are authorised by the European Union and other regulatory agencies, such as the USDA, for drug manufacturing. These facilities are able to supply all our customers globally and are expecting to triple our production capacity in the coming years.